Invirsa
Pharmaceuticals, 1275 Kinnear Rd, Columbus, Ohio, 43212, United States, 1-10 Employees
Who is INVIRSA
Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associa...
Read More
-
Headquarters: 1275 Kinnear Rd, Columbus, Ohio, 43212, United States
-
Date Founded: 2014
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 8011
|
NAICS Code: 621111 |
Show More
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Invirsa
Answer: Invirsa's headquarters are located at 1275 Kinnear Rd, Columbus, Ohio, 43212, United States
Answer: Invirsa's phone number is FALSE
Answer: Invirsa's official website is https://invirsa.com
Answer: Invirsa's revenue is $1 Million to $5 Million
Answer: Invirsa's SIC: 8011
Answer: Invirsa's NAICS: 621111
Answer: Invirsa has 1-10 employees
Answer: Invirsa is in Pharmaceuticals
Answer: Invirsa contact info: Phone number: FALSE Website: https://invirsa.com
Answer: Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury. In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials. Invirsas initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month